country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992540

Copy Link Print Information

IBI389

IBI389 is an anti-Claudin18.2 × CD3 bispecific antibody. IBI389 binds CD3 and Claudin18.2 to engage T cells, induce immune synapse formation, and redirect T cell killing of Claudin18.2-positive tumors. IBI389 increases intratumoral CD3⁺/CD8⁺ T cells, an immuno-inflammatory phenotype, shortens tumor-T cell distance, compensatorily increases regulatory T cells, and elevates IL-2/IFN-γ; IL-4/IL-10/IL-17A/TNF-α are decreased. IBI389 can be used in gastric cancer-related research.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

IBI389 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Target
- Conjugated
- 신청
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Species Reactivity

Human

IC₅₀ & Target

^[1]

IL-10

IL-17A

IL-4

IL-2

TNF-α

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

In Vivo

IBI389 (1-10 mg/kg; i.v.; every 2 weeks) suppresses tumor growth and increases intratumoral CD3⁺ T-cell infiltration in the AGS gastric cancer xenograft, with the greatest tumor control and immune infiltration when combined with PD-1 blockade^[1].
IBI389 (1-10 mg/kg; i.v.; every 2 weeks) suppresses tumor growth and increases intratumoral CD3⁺ T-cell density in the KPC pancreatic cancer model, and combination with PD-1 blockade provides the strongest tumor inhibition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Cancer Immunology

Target

Claudin18.2 & CD3

Conjugated

Unconjugated

신청

ELISA, FACS, Functional assay

Chemical Information

SMILES

[IBI389]
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Zhu Y, et al. The claudin-18.2-CD3 bispecific antibody IBI389 exerts an antitumor effect on malignant tumors with positive claudin-18.2 expression by promoting T-cell infiltration and remodeling the tumor immune microenvironment. Translational Cancer Research. 2026;15(3).

[2]. Li X, et al. Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. BMC medicine. 2026 Jan 16;24(1):91.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Target
- Conjugated
- 신청
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

IBI389

All Interleukin Related Isoforms

All TNF Receptor Isoforms